Overall rank by patents
#11,223
of 50,000 tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Corsair Pharma, Inc.
USPTO PatentsView assignee record - 27 granted patents across 4 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (HETEROCYCLIC COMPOUNDS).
27
Total patents granted
4
CPC technology areas
17.4
Avg claims per patent
-14%
5-year grant velocity
The verdict
According to USPTO PatentsView, Corsair ranks #11,223 of 50,000 tracked US assignees by granted-patent volume, with 27 patents across 4 technology areas.
- #11,223
- of 50,000 US assignees by volume
- Top 58%
- by Innovation Score (32.7/100)
- 17.4
- avg claims per patent
- -14%
- grant velocity, last 5 yrs
Portfolio overview
Corsair Pharma, Inc. has been granted 27 US utility patents between 2016 and 2025, placing Corsair Pharma, Inc. at #11,223 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.4 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a US Corporation, Corsair Pharma, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Corsair sits between Clearmotion Acquisition I Llc (27 patents, rank #11,220) and DL Technology, Llc. (27 patents, rank #11,228) - the closest US assignees by grant volume. The composite Innovation Score of 32.7/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 12 grants, compared with 14 in the 2015–2019 window, a -14% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Corsair Pharma, Inc.'s 17.4 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 4 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Who files at Corsair's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Clearmotion Acqui…
ClearMotion Acquisition I LLC
27 patents
- Contentful
Contentful GmbH
27 patents
- Corentec
Corentec Co., Ltd.
27 patents
- Corium Internatio…
Corium International, Inc.
27 patents
- Delphi Automotive…
DELPHI AUTOMOTIVE SYSTEMS LUXEMBOURG SA
27 patents
- Denso
DENSO ELECTRONICS CORPORATION
27 patents
- Dimaag-ai
DIMAAG-AI, Inc.
27 patents
- DL Technology
DL Technology, LLC.
27 patents
- Corsair Pharma ◀
Corsair Pharma, Inc.
27 patents
What this shows Corsair holds 27 patents at rank #11,224, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Corsair
By rank, the assignees closest to #11,224 in granted patent volume.
- Clearmotion Acquisition I Llc #11,220 · 27 patents
- Contentful Gmbh #11,221 · 27 patents
- Corentec Co., Ltd. #11,222 · 27 patents
- Corium International, Inc. #11,223 · 27 patents
- Delphi Automotive Systems Luxembourg Sa #11,225 · 27 patents
- Denso Electronics Corporation #11,226 · 27 patents
- Dimaag-ai, Inc. #11,227 · 27 patents
- DL Technology, Llc. #11,228 · 27 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Corsair's primary technology class.
Corsair's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
33 Top 58% higher than 42% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 3 | 11.1% |
| 2017 | 4 | 14.8% |
| 2018 | 2 | 7.4% |
| 2019 | 5 | 18.5% |
| 2020 | 3 | 11.1% |
| 2021 | 3 | 11.1% |
| 2022 | 3 | 11.1% |
| 2023 | 1 | 3.7% |
| 2024 | 2 | 7.4% |
| 2025partial year | 1 | 3.7% |
Which technologies does Corsair Pharma, Inc. patent most?
Top 4 of 4 technology areas
Grant record at a glance
Portfolio Volume 27 grants
CPC subclasses 4
Avg. claims / grant 17.4
Velocity -14%
Historical grant data only; it does not rate legal strength or current strategy.
Frequently Asked Questions
Where does Corsair Pharma, Inc. rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Corsair Pharma, Inc. ranks #11,223 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Corsair Pharma, Inc. hold?
Corsair Pharma, Inc. holds 27 US utility patents granted between 2016 and 2025, spanning 4 technology areas.
What is Corsair Pharma, Inc.'s Innovation Score?
Corsair Pharma, Inc. has an Innovation Score of 32.7 out of 100 (top 58% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Corsair Pharma, Inc. focus on?
Corsair Pharma, Inc.'s top technology area is C07D (HETEROCYCLIC COMPOUNDS) with 27 patents. Grants appear in 4 CPC subclasses total.
Is Corsair Pharma, Inc.'s patent grant rate increasing or decreasing?
Corsair Pharma, Inc.'s recent grant velocity is -14% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.
What does claim depth mean for Corsair Pharma, Inc.'s patents?
Corsair Pharma, Inc.'s patents average 17.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Corsair Pharma, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Corsair's 27 grants land it in the top 58% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Corsair ranks #11,223 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07D - see who else leads that technology area. C07D leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.